Welcome to NLS Pharmaceutics

We are seeking to design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are seeking to create new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Room

Interview with Alex Zwyer, CEO of NLS Pharmaceutics Ltd. (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section

Latest News

  • May 18, 2021
    NLS Pharmaceutics Announces New Study Data Confirming Mazindol’s Unique Orexin Pathway Activation for Treating Narcolepsy
  • May 5, 2021
    NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)
  • Apr 5, 2021
    NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
  • Mar 29, 2021
    NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)
Contact us

NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.

Alter Postplatz 2
CH-6370 Stans NW

T: +41 41 618 80 00
F: +41 41 618 80 09

Your Name (required)

Your Email (required)


Your Message